Discover how Touchlight's innovative mbDNA™ platform is redefining precision gene editing and accelerating your genetic medicine projects
- Why mbDNA™ is redefining precision gene editing - Platform improves cell viability and edited cell yields - Delivers proven performance in real-world applications
Access the Executive Summary
Partners
Platform Technology Licenses
World's First
GMP-Licensed Cell-Free DNA Facility
Touchlight operates the first GMP-licensed facility for producing synthetic DNA using a completely cell-free enzymatic process.
>1500
Batches
To date, Touchlight has produced over 1500 batches of cell-free DNA using its proprietary dbDNA™ platform.
Tripled
Manufacturing Capacity in 2024
Touchlight recently tripled its production capacity with a major expansion of its Morelands facility in London.
About Touchlight
At Touchlight, we’ve reimagined DNA production to meet the evolving needs of innovators like you. Our patented synthetic DNA vector, dbDNA™, and cell-free enzymatic manufacturing platform deliver DNA with unmatched speed, scale, and purity, helping you move faster from discovery to clinic.
